Discover how CRISPR–Cas9 is evolving from a genome-editing lab tool into a programmable protein drug. Explore viral vectors, lipid nanoparticles, and peptide-based delivery strategies that enable safe, one‑time gene editing therapies for diseases like sickle cell and inherited retinal disorders.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs